FORM 4

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

## STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL

OMB Number: 3235-0287 Estimated average burden hours per response: 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person*  MUELLER PETER  (Last) (First) (Middle)  C/O VERTEX PHARMACEUTICALS INCORPORATED  130 WAVERLY STREET					<u>V</u>	Issuer Name and Ticker or Trading Symbol     VERTEX PHARMACEUTICALS INC /     MA [ VRTX ]      Indeed the second of the sec								neck all appl Direct V Office	ationship of Reportin k all applicable) Director Officer (give title below)		son(s) to Iss 10% Ov Other (s below)	vner	
															EVP, Global R&D, CSC				
(Street)			02139		- 4. li	f Amer	idmer	nt, Date	of Origi	inal Fil	led (Month/D	ay/Year)	6. I	X Form	filed by One	e Repo	g (Check Ap orting Perso n One Repo	n	
(City)	(St	tate)	(Zip)																
		Tab	le I - N	on-Deri	vative	Sec	uriti	ies A	cquire	d, D	isposed o	of, or B	eneficia	ly Owne	d				
1. Title of Security (Instr. 3)		2. Transaction Date (Month/Day/Year)		2A. Deemed Execution Date, if any (Month/Day/Year)		3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 ar			Benefic Owned	ies ially Following	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of Indirect Beneficial Ownership				
									Code	v	Amount	(A) or (D)	Price	Reporte Transa (Instr. 3	ction(s)			(Instr. 4)	
Common Stock Common Stock			11/15/2010 11/15/2010		-			М		1,600 1,600	A D	\$10.41	. 12	120,834 119,234		D			
								S <sup>(1)</sup>				\$34.43(2	)(3) 11			D			
												4	4,150		I	401(k)			
		7	able I								posed of , converti			Owned					
Security or Ex (Instr. 3) Price Deriv	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	Executifi any	3A. Deemed Execution Date, if any (Month/Day/Year)		4. Transaction Code (Instr. 8)				Exerc tion Da h/Day/Y		7. Title and Amount of Securities Underlying Derivative Secur (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number derivative Securities Beneficially Owned Following Reported Transaction (Instr. 4)	lly	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
				Cod	Code	v	(A)	(D)	Date Exercisable		Expiration Date	Title	Amount or Number of Shares						
Stock	\$10.41	11/15/2010			М			1 600	(4)	)	02/02/2015	Common	1 600	90	16.800	, 1	D		

## **Explanation of Responses:**

- 1. Transaction made pursuant to Dr. Mueller's company approved trading plan under Rule 10b5-1.
- 2. Open market sales reported on this line occurred at a weighted average price of \$34.43 (range \$33.95 to \$34.57).
- 3. Dr. Mueller undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
- 4. Fully vested.

## Remarks:

Kenneth S. Boger, Attorney-In-11/16/2010

**Fact** 

\*\* Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.